DealsAug 12, 2026, 05:03 PM
PolyPid Licenses D-PLEX100 to Azurity for $30M Upfront, $290M+ Milestones
AI Summary
PolyPid Ltd. announced a significant License and Supply Agreement with Azurity Pharmaceuticals Ireland Ltd. for D-PLEX100 in the United States and Canada, including $30 million in upfront and near-term payments and potential milestones exceeding $290 million, plus tiered royalties. This positive development comes alongside the company's interim financial results for the six months ended June 30, 2026, which showed a net loss of $15.58 million and a cash balance of $6.56 million. The company also disclosed substantial doubt about its ability to continue as a going concern.
Key Highlights
- Entered into an exclusive License and Supply Agreement with Azurity Pharmaceuticals for D-PLEX100 in the U.S. and Canada.
- Received an upfront payment of $15 million and an additional $15 million upon FDA NDA acceptance.
- Eligible to receive over $290 million in additional regulatory, development, and sales-based milestone payments.
- Will receive tiered royalties ranging from mid-teen to mid-twenties percentages on product sales.
- Reported a net loss of $15.58 million for the six months ended June 30, 2026, compared to $18.25 million in 2025.
- Cash and cash equivalents were $6.56 million as of June 30, 2026.
- Accumulated deficit reached $317.08 million as of June 30, 2026.
- Management noted substantial doubt about the company's ability to continue as a going concern.
Price Impact
More from PYPD